Table 1.
Study subjects for the assessment of IL-22 and IL-22BP in the blood
| Category | N = 141 | Male/female ratio | Age at blood draw (years)a | EDSSa | Disease duration (years)a | Last relapse (months)a |
|---|---|---|---|---|---|---|
| Clinically active MS patients | 26 | 7/19 | 31.5 ± 10.0 | 2.00 ± 1.00 | 0.63 ± 7.19 | 0.46 ± 0.82 |
| Clinically inactive MS patients | 35 | 10/25 | 39.5 ± 11.5 | 1.50 ± 0.63 | 7.00 ± 9.25 | 16.87 ± 34.43 |
| Progressive MS patients | 35 | 12/23 | 52.0 ± 15.0 | 4.50 ± 2.50 | 17.0 ± 12.0 | – |
| Healthy control subjects | 45 | 21/24 | 34.0 ± 28.5 | – | – | – |
MS multiple sclerosis, EDSS expanded disability status scale
aMedian ± interquartile range